NEW BRIGHTON, Minnesota--(BUSINESS WIRE)--
Cellectis (Paris:ALCLS), the global genome engineering specialist,
announces the issuance by the USPTO of a 4th US
patent (US 8,697,853) directed to TAL-effector nucleases.
On April 15, 2014, the USPTO issued a fourth patent to the University of
Minnesota and the Iowa State University for the TALENTM
technology developed by Cellectis.
This patent US 8,697,853 is more particularly drawn to the genomic
sequences encoding TAL-effector nucleases. These proteins developed
jointly by researchers at the University of Minnesota and Iowa State
University can “read” DNA and make pinpoint cuts in targeted genes.
This fourth issued patent, like the previous ones, is part of a patent
portfolio owned by the Regents of the University of Minnesota and Iowa
State University Research Foundation and licensed exclusively to
Cellectis as per a license agreement of January 2011.
The inventors of these patents are Pr. Daniel Voytas, from the
University of Minnesota who is also acting as Chief Scientific Officer
of Cellectis Plant Sciences in New Brighton (MN), Pr. Adam Bogdanove
formerly of Iowa State University and currently of Cornell University,
and Dr. Feng Zhang, who is now Chief Operating Officer of CellectisPlant Sciences.
Cellectis is a biopharmaceutical company
focused on oncology. The company’s mission is to develop a novel
generation of therapy based on engineered T cells to treat cancer.
Cellectis capitalizes on its 14 years of expertise in genome
engineering, based on TALEN™, meganucleases and the state-of-the-art
electroporation technology Pulse Agile, to create a new generation of
cancer immunotherapy for treating leukemias and solid tumors. Cellectis
adoptive cancer immunotherapy for chronic and acute leukemias is based
on the first allogeneic T cell chimeric antigen receptor (CAR)
technology. CAR technologies are designed to target surface antigens
expressed on cells. These treatments reduce toxicities associated with
current chemotherapeutics and have the potential for curative therapy.
The Cellectis Group is focused on life sciences and uses leading genome
engineering technologies to build innovative products in various fields
and markets. Cellectis is listed on the NYSE Alternext market (ticker:
ALCLS). To find out more about us, visit our website: www.cellectis.com.
This press release and the information contained
herein do not constitute an offer to sell or subscribe, or a
solicitation of an offer to buy or subscribe, for shares in Cellectis in
any country. This press release contains forward-looking statements that
relate to the Company’s objectives based on the current expectations and
assumptions of the Company’s management only and involve risk and
uncertainties that could cause the Company to fail to achieve the
objectives expressed by the forward-looking statements above.
+33 (0)1 81 69 16 00